MeSH D005185 - fallopian tube neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Bevacizumab | Abevmy | 2021-04-21 | |||
| Bevacizumab | Lextemy | |||||
| GSK | Niraparib | Zejula | 2027-08-12 | 2017-03-27 | ||
| Roche | Bevacizumab | Avastin | 2005-01-12 | $1,988.958 M | Q4/22-Q3/23 | |
| Pfizer | Bevacizumab | Zirabev | 2019-06-27 | $424 M | Y2023 | |
| Amneal Pharmaceuticals | Bevacizumab | Alymsys | 2022-04-13 | |||
| Celltrion | Bevacizumab | Vegzelma | 2022-09-27 | |||
| Genentech | Bevacizumab | Avastin | 2004-02-26 | |||
| Amgen | Bevacizumab | Mvasi | 2017-09-14 | |||
| Stada Arzneimittel | Bevacizumab | Oyavas | 2021-03-26 | |||
| Samsung Bioepis | Bevacizumab | Aybintio | 2020-08-19 | |||
| Bevacizumab | Onbevzi | 2021-01-11 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
77%95/123
Phase 2
20%30/150
Phase 3
13%6/45
Approved: 4Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use